Who we are

BioCurate is a bold, collaborative venture, dedicated to translating Australia’s research potential to drive economic returns and health impacts worldwide. Created jointly by two of Australia’s leading biomedical universities – the University of Melbourne and Monash University – with the support of the Victorian government, we identify promising biomedical research and help accelerate its development into new therapies. We are operationally independent, with a team that brings decades of scientific and commercial expertise, enabling us to recognise and realise real-world potential and providing a critical bridge, aligning the efforts and interests of industry and academia.
We can help you change the future.

We bridge the gap

Our collaborative team of global biomedical experts bridge the gap between:

Academia + Industry
Ideas + Impact
Discovery + Partnerships
Collaboration + Commercialisation
Research + Translation

What we are doing

The BioCurate team

Our team

200
Has over 200 years of combined biotech/pharma industry experience

39
Has been directly involved in over 39 Investigational New Drug applications (INDs)

72
Are responsible for 72 therapeutics currently in the clinic

$3.9B
Were directly involved in 15 deals worth a cumulative total of more than $3.9 billion

Twitter feed

Congratulations to Prof Andrew Wilkson being appointed as an Honorary Melbourne Enterprise Professor at @Bio21Institute! It is fantastic to see a notable biotech industry leader be recognised in academia with this appointment. @unimelb

Congratulations to the team at @Certara on their recent IPO success, raising just under $670 million. We are excited to see another biotech company dedicated to accelerating drug development achieve another milestone https://nuvi.me/ynw8i4

Commercially available antibodies have become key tools in pre-clinical studies. But should we trust them? Read more about industry’s perspective on research antibodies and how best to use them in an early-stage project https://nuvi.me/68qijw